Financial Data and Key Metrics Changes - The company reported a profit of $26 million in the first half of 2024, with revenue from marketed products increasing by 64% at constant exchange rates to $128 million [9] - Consolidated oncology revenue reached $168 million, on track to meet the full-year revenue guidance of $300 million to $400 million [9][10] - R&D expenditures decreased to $95 million due to strategic reorganization and project prioritization [9] Business Line Data and Key Metrics Changes - Fruquintinib's U.S. market sales exceeded $130 million in the first half, indicating strong early uptake [7] - In China, all products experienced double-digit growth, contributing to a combined in-market sales growth of 145%, primarily driven by Fruquintinib U.S. sales [7] - The company is preparing for the launch of savolitinib in the U.S. later this year [6] Market Data and Key Metrics Changes - The U.S. market for Fruquintinib showed strong performance, with expectations for Japan and EU launches later in the year [11] - The competitive landscape in China remains challenging, yet the company maintains its market leadership in the third-line metastatic colorectal cancer (mCRC) segment [11] Company Strategy and Development Direction - The company is focused on globalization and self-sustainability, with plans to launch Fruquintinib worldwide in partnership with Takeda [6] - The pipeline includes multiple products under review, with a focus on life cycle indications for existing products and new product launches [7][14] - The company aims to achieve profitability potentially ahead of the previously set target of 2025 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of 2024, highlighting numerous upcoming events that could fuel growth [23] - The company is actively preparing for market launches and is optimistic about the regulatory approval processes for its products [34][38] Other Important Information - The company maintains a strong cash position of over $800 million, allowing for continued investment in R&D and commercial operations [10][64] - The company is engaged in ongoing business development discussions and is focused on clinical development globally [34] Q&A Session Summary Question: Insights on SAVANNAH data and U.S. submission leadership - Management confirmed that AstraZeneca is leading the trial and NDA submission, with the company contributing to the package [26][28] Question: Sales guidance for Fruquintinib and EU strategy - Management indicated that there are no updates on sales guidance from Takeda, but they expect a launch in Europe before the end of the year [33][34] Question: Regulatory approval status for second-line gastric cancer - The NDA review is ongoing, with an anticipated decision in Q3 2024 [38] Question: Feedback on Fruquintinib's U.S. sales and patient demographics - Management noted that they do not have clarity on patient demographics but emphasized the drug's unique pharmacological profile [56] Question: R&D expenditure outlook for the second half of the year - Management expects R&D investment to increase in the second half, although it will still be less than the previous year [48] Question: Exploration of additional indications for Tazemetostat - Management confirmed ongoing studies for Tazemetostat in second-line follicular lymphoma and other potential solid tumors [50][53] Question: Use of surplus capital - Management plans to gradually increase investments in R&D and commercial operations rather than returning capital to shareholders [64]

ADVANCING TO GLOBAL LAUNCHES & CONTINUED PIPELINE PROGRESS H1 2024 RESULTS & BUSINESS UPDATES July 31, 2024 Nasdaq/AIM:HCM | HKEX:13 looop HUTCHMED Safe harbor statement & disclaimer The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation R ...

Exhibit 99.1 HUTCHMED Reports 2024 Interim Results and Provides Business Updates Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 31, 2024: HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Pu ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 收入增長勢頭持續，現金結餘充裕支持擴展 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 呋喹替尼全球佈局持續推進，管線進一步拓寬並取得切實進展 （於開曼群島註冊成立的有限公司） 1 / 70 （股份代號：13） 和黃醫藥公佈2024年中期業績及最新業務進展 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」、「本公司」或「我們」）今日公佈截至2024年6月30日止六個月的 財務業績以及提供關鍵臨床項目和商業化發展的最新進展。 公司將於今天中國香港時間晚上8時/英國夏令時間下午1時/美國東部夏令時間上午8時舉行網絡直播（英語場 次），並於2024年8月1日（星期四）中國香港時間上午8時30分舉行中文（普通話）場次。投資者登記後可透過 和黃醫藥網站（www.hutch-med.com/event）參與實時網絡直播。 除另有說明外，所有金額均以美元列示。 • 重申2024年全年腫瘤/免疫業務 ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, August 1, 2024. After registration, investo ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][7]. Core Insights - The company showcased significant progress in its innovative drug pipeline during the R&D Day held on July 9, 2024, highlighting the clinical data and market potential of its candidate drugs [3]. - The company has a strong competitive edge with its innovative pipeline, which includes promising candidates such as Syk inhibitor, Sovanertinib, and HMPL-306, each targeting specific diseases with substantial market potential [4]. - Future catalysts for the company include the anticipated growth in overseas sales of Fuquintinib, ongoing clinical trials for various indications, and expected regulatory approvals that could drive revenue growth [5]. Summary by Sections Company Events - On July 9, 2024, the company held an R&D Day where management shared insights on clinical data and market value of its innovative pipeline, including Syk inhibitor for autoimmune diseases, Sovanertinib for pancreatic cancer, and HMPL-306 for acute myeloid leukemia [3]. Candidate Pipeline Progress - Syk Inhibitor: Demonstrates superior selectivity and safety profile, with ongoing clinical trials showing promising results for ITP and wAIHA [4]. - Sovanertinib: Shows improved progression-free survival (PFS) and overall survival (OS) in combination with PD1 and chemotherapy for pancreatic cancer [4]. - HMPL-306: Targets IDH1/2 mutations in acute myeloid leukemia, with a registration-phase III trial initiated [4]. Future Catalysts - Fuquintinib's overseas sales are expected to grow, with a potential approval in Japan in the second half of 2024 [5]. - The company anticipates new sales growth from domestic approvals for various indications, including gastric cancer and other cancer therapies [5]. - The company has a robust cash position of $886 million as of the end of 2023, supporting its growth strategy [5]. Financial Forecast and Valuation - The company projects total revenue of $300 million to $400 million in 2024, driven by existing product sales and royalties [5]. - Revenue estimates for 2024-2026 are $705 million, $912 million, and $1.185 billion, respectively, with a calculated equity value of HKD 40.9 billion based on DCF analysis [5][6].

[ T able_StockInfo] 2024 年 07 月 10 日 证券研究报告•公司动态跟踪报告 买入 (维持) 当前价:27.00 港元 和黄医药(0013.HK)医疗保健 目标价:34.30 港元 商业化表现靓眼,管线持续释放创新潜力 [Table_Summary 事件:7 月 9 日,] 和黄医药举办研发日交流,管理团队分享和黄医药丰富且创新 的候选药物管线中的部分项目的最新进展,包括索乐匹尼布用于治疗免疫性血小板 减少症的 ESLIM-01 III 期研究,以及用于治疗温抗体型自身免疫性溶血性贫血的 ESLIM-02 II/III 期研究;索凡替尼用于治疗胰腺导管腺癌的 II/III 期研究;以及 HMPL-306 用于治疗急性髓系白血病的 RAPHAEL III 期研究。 呋喹替尼美国商业化推进顺利,获 EMA批准上市。呋喹替尼于 2023年 11 月 9 日获 FDA 批准上市,上市以来到 3 月底美国销售额达 101 亿日元(约合美元 6500 万)。呋喹替尼于 2024年 6月在欧盟获得经治转移性结直肠癌的批准,有 望于 2024年年底前在日本获得经治转移性结直肠癌的批准。呋喹替尼二线 ...

浦银国际研究 公司研究 | 医药行业 浦银国际 公司研究 16. 7 21. 7 26. 7 31. 7 36. 7 41. 7 和黄医药 27 32 37 42 47 52 57 和黄医药(HCM.US/13.HK):索乐匹尼布 出海可期 阳景 首席医药分析师 Jing_yang@spdbi.com (852) 2808 6434 胡泽宇 CFA 医药分析师 ryan_hu@spdbi.com (852) 2808 6446 2024 年 7 月 10 日 和黄医药 (HCM.US) 目标价(美元) 25.0 潜在升幅/降幅 +48% 目前股价(美元) 16.9 52 周内股价区间(美元) 11.9-21.9 总市值(百万美元) 2,936 近 3 月日均成交额(百万) 2 市场预期区间 US$16.9 US$25.0 US$45.0 US$17.5 SPDBI 目标价 目前价 市场预期区间 注:数据截至 2024 年 7 月 9 日 资料来源:Bloomberg、浦银国际 (HCM.US/13.HK) 市场预期区间 HK$39.0 HK$61.9 HK$34.3 HK$27.0 SPDBI 目标价 目前价 ...

各位投资者大家听众好,欢迎大家加入我们国营盛事300家云端店的经商分类购物活动,目前是我们和黄医药的交流专场,今天我们非常荣幸的邀请到了和黄医药负责投资者关系活动的石明总来和我们进行线上的交流,那在开始我们还是邀请石明总为我们介绍一下公司近期的进展,我们近期也是看到了福克斯迪尼是正式获得了欧盟委员会的提名, 好的,谢谢各位,非常感谢大家能够有时间来跟我们交流那这边我先简单介绍一下,后面有问题的话大家再提问讨论 我们是一家专注于这个肿瘤创相的一家生物医药公司我们是成立于这个两千年左右那么总部呢是在上海这个张江这边其实公司这个成立的时间其实也非常长了那么可能过往国内投资者对我们不是特别了解的话主要是因为我们之前一开始的话是在海外上市那么最早是在06年在这个英国上市然后后面 2016年在美国纳斯达夫上市然后的话到了2021年最后才在这个港股上市所以我们回港股的时间比别的公司可能稍微晚一些所以可能国内投资者这边对我们就相对来说没有那么熟悉那么今天我稍微结合一下我们这个年报的情况稍微跟大家介绍一下有可能部分投资者可能不是特别熟悉啊我们大家可以看我们去年整个这边的话 我们业务上其实是两块一块是叫肿瘤免疫的业务这个的话去年 ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English co ...